Gout Pipeline Landscape Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 29, 2021--
The “Gout - Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Gout - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.
Gout Emerging Drugs Chapters
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gout Emerging Drugs
SEL 212: Selecta Biosciences
Selecta Bioscience’s lead drug candidate, SEL 212, is a novel combination product consisting of pegadricase (also known as pegsiticase) co-administered with synthetic vaccine particles encapsulating rapamycin (SVP-R). The drug has demonstrated good efficacy and was well tolerated in its phase II trials and is currently being evaluated for the chronic gout in its phase III trials.
URC 102: JW Pharmaceuticals
JW Pharmaceuticals “breakthrough” drug UC-102 is currently being evaluated for the treatment of gout and has demonstrated good safety and efficacy profile in phase II trials. ULC-102 is an antigout small molecule with SLC22A12 protein inhibition mechanism of action and promotes uric acid excretion.
Major Players in Gout
There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.
Gout: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Key Questions Answered
- How many companies are developing Gout drugs?
- How many Gout drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gout and their status?
- What are the key designations that have been granted to the emerging drugs?
- Selecta Biosciences
- JW Pharmaceuticals
- Revive Therapeutics
- Fuji Yakuhin Co., Ltd.
- Arthrosi Therapeutics
- SEL 212
- URC 102
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/nd2o6n
View source version on businesswire.com:https://www.businesswire.com/news/home/20210929005589/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 09/29/2021 09:28 AM/DISC: 09/29/2021 09:28 AM